Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
134,382
Completed, any sponsor type
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting22,408
- Not yet recruiting9,484
- Completed134,382
134,382 trials
Showing 1 to 25, recently updated first.
- Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisPivotal-lookingCompleted
United TherapeuticsIndustry
NCT04708782 · 598 participants · Start Apr 21, 2021 · Primary completion Feb 2, 2026
Drug: Placebo; Inhaled Treprostinil · For: Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 96 sites in all
- Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' DiseaseCompleted
Northwell HealthAcademic, hospital or other
NCT07369063 · 5 participants · Start Aug 25, 2025 · Primary completion Oct 29, 2026
Drug: Ergocalciferol 50,000 IU; Methimazole · For: Graves Disease; Graves' Disease; Hyperthyroidism
Sites: New Hyde Park, New York
Guangdong Jianersheng Pharmaceutical Technology Co., Ltd.Academic, hospital or other
NCT07057414 · 22 participants · Start Jul 7, 2025 · Primary completion Jan 26, 2026
Drug: GMDTC for injection · For: Cadmium Exceeds the Standard
Sites: Guangzhou, China
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT07600905 · 245 participants · Start Nov 1, 2019 · Primary completion Aug 31, 2025
Drug: Avatrombopag 40 mg oral tablet; Recombinant Human Thrombopoietin(rhTPO) · For: Postoperative Complication; Severe Thrombocytopenia; Liver Transplantation (LT)
Sites: Shanghai, China
- A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and ObesityPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT06037252 · 414 participants · Start Sep 21, 2023 · Primary completion Jan 8, 2026
Drug: Tirzepatide; Placebo · For: Type 2 Diabetes; Obesity
Sites: Phoenix, Arizona; Concord, California; Sacramento, California · 40 sites in all
- Assessing Gingivitis and Plaque From a Marketed ToothpastePivotal-lookingCompleted
Procter and GambleIndustry
NCT07158112 · 120 participants · Start Aug 30, 2025 · Primary completion Dec 7, 2025
Drug: Stannous Fluoride Dentifrice; Test Stannous Fluoride Dentifrice and 1 more · For: Gingivitis
Sites: Whitter, California
Novartis PharmaceuticalsNovartis (NVS)
NCT04543331 · 572 participants · Start Mar 18, 2020 · Primary completion Nov 17, 2025
Drug: brolucizumab · For: Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME)
Sites: Munich, Germany; Neuburg A.d. Donau, Germany; Würzburg, Germany · 41 sites in all
- Evaluation of Tonabersat for DMEPivotal-lookingCompleted
Jaeb Center for Health ResearchAcademic, hospital or other
NCT05727891 · 129 participants · Start May 2, 2023 · Primary completion Jan 15, 2026
Drug: Tonabersat · For: Diabetic Macular Edema
Sites: Huntington Beach, California; Loma Linda, California; Oakland, California · 28 sites in all
- Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early DementiaCompleted
Emory UniversityAcademic, hospital or other
NCT04522739 · 27 participants · Start Sep 6, 2022 · Primary completion Sep 23, 2025
Drug: Spironolactone; Placebo · For: Mild Cognitive Impairment; Alzheimer Disease
Sites: Atlanta, Georgia
Medical College of WisconsinAcademic, hospital or other
NCT03571334 · 42 participants · Start Jul 8, 2020 · Primary completion Sep 5, 2023
Drug: IncobotulinumtoxinA (Xeomin®, Merz) (INA); Normal saline · For: Peripheral Neuropathy Due to Chemotherapy
Sites: Milwaukee, Wisconsin
RSUP PersahabatanAcademic, hospital or other
NCT07951346 · 28 participants · Start Feb 1, 2026 · Primary completion Sep 14, 2026
Drug: N-acetylcysteine (NAC) · For: Drug-Induced Liver Injury; Tuberculosis
Sites: Jakarta, Indonesia
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT02484417 · 32 participants · Start Jul 21, 2015 · Primary completion Aug 10, 2016
Drug: RSV A2 · For: Upper Respiratory Tract Infection
Sites: Bethesda, Maryland
National Cancer Institute (NCI)NIH
NCT01352962 · 18 participants · Start Sep 26, 2011 · Primary completion Feb 7, 2017
Drug: Gemcitabine; Carboplatin and 1 more · For: Urethral Neoplasms; Neoplasms, Urethral; Cancer of the Urethra and 1 more
Sites: Bethesda, Maryland
- Study of Smith-Lemli-Opitz SyndromeCompleted
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00001721 · 130 participants · Start Sep 13, 1998
Drug: Cholesterol Suspension; CRH and 1 more · For: Smith-Lemli-Opitz Syndrome
Sites: Bethesda, Maryland
- Celiac Versus Splanchnic Neurolysis in Abdominal MalignanciesPivotal-lookingCompleted
Pain Medicine DepartmentAcademic, hospital or other
NCT07949981 · 60 participants · Start Mar 15, 2026 · Primary completion Sep 1, 2026
Drug: Celiac Plexus Block; Splanchnic nerve block · For: Abdominal Malignancy
Sites: Lahore, Pakistan
Sanliurfa Education and Research HospitalGovernment (non-federal)
NCT07951710 · 84 participants · Start Sep 23, 2023 · Primary completion Feb 15, 2024
Drug: Fentanyl (IV) · For: Breast Neoplasms; Pain, Postoperative
Sites: Gaziantep, Turkey (Türkiye)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
NCT05953350 · 29 participants · Start Nov 7, 2023 · Primary completion May 7, 2024
Drug: 600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib; RP2D dose of 600mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial. · For: Inhibition of Autophagy Synergizes Anti-tumor Effect
Sites: Guangzhou, China
- SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And SurvivalPivotal-lookingCompleted
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT04415060 · 800 participants · Start Jun 15, 2020 · Primary completion Mar 17, 2025
Drug: Isoflurane Inhalant Product; Sevoflurane inhalant product · For: Covid19; Hypoxic Respiratory Failure
Sites: Edmonton, Canada; London, Canada; Ottawa, Canada · 13 sites in all
- Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent ExacerbationsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT04053634 · 689 participants · Start Aug 26, 2019 · Primary completion Jul 28, 2025
Drug: Benralizumab; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Surprise, Arizona; Little Rock, Arkansas; Los Angeles, California · 342 sites in all
- A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini StrokePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT05686070 · 12,327 participants · Start Jan 26, 2023 · Primary completion Oct 23, 2025
Drug: Asundexian (BAY2433334); Placebo · For: Prevention of Ischemic Stroke; Acute Non-cardioembolic Ischemic Stroke; High-risk Transient Ischemic Attack
Sites: Fairhope, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 741 sites in all
University of North Carolina, Chapel HillAcademic, hospital or other
NCT06352073 · 23 participants · Start May 16, 2024 · Primary completion Apr 16, 2026
Drug: Dupilumab · For: Eosinophilic Esophagitis; EoE
Sites: Chapel Hill, North Carolina
University of WashingtonAcademic, hospital or other
NCT04387227 · 22 participants · Start Mar 18, 2021 · Primary completion Sep 12, 2025
Drug: Carboplatin; Pembrolizumab · For: Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Sites: Seattle, Washington
National Institute of Neurological Disorders and Stroke (NINDS)NIH
NCT02511028 · 14 participants · Start Nov 27, 2015 · Primary completion Aug 1, 2018
Drug: Ferumoxytol · For: Multiple Sclerosis
Sites: Bethesda, Maryland
National Cancer Institute (NCI)NIH
NCT03952598 · 42 participants · Start Oct 16, 2019 · Primary completion Oct 28, 2026
Drug: HP 13C Pyruvate · For: Glioma; Gliomas; High Grade Glioma and 2 more
Sites: Bethesda, Maryland
- Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast CancerCompleted
GE HealthcareIndustry
NCT05486182 · 153 participants · Start Feb 8, 2022 · Primary completion Apr 18, 2025
Drug: 18F Fluoroestradiol Radiopharmaceutical with PET/CT · For: Metastatic Breast Cancer
Sites: Dijon, France; La Tronche, France; Limoges, France · 11 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.